PMID: 6111632Mar 7, 1981Paper

Benzodiazepine withdrawal symptoms and propranolol

Lancet
P J TyrerT Huggett

Abstract

40 patients seen in general practice and psychiatric outpatient clinics who had taken lorazepam or diazepam alone in regular dosage for a mean period of 3.6 years had their benzodiazepine replaced by propranolol (60--120 mg/day) or placebo for two weeks under double-blind conditions. Depending on the criteria for the definition of an abstinence syndrome, 27--45% of the patients had withdrawal symptoms during the study. Propranolol did not affect the drop-out rate or the incidence of withdrawal symptoms but significantly reduced their severity in patients completing the study. The percentage fall in serum levels of desmethyldiazepam in patients who experienced withdrawal symptoms after stopping diazepam was significantly greater in patients with no withdrawal symptoms.

References

Feb 1, 1976·Acta Psychiatrica Scandinavica·K Fruensgaard
Mar 11, 1978·Lancet·G Mendelson
Sep 15, 1978·Science·A KalesJ D Kales
Oct 7, 1978·British Medical Journal·P Tyrer
Oct 1, 1978·The Alabama Journal of Medical Sciences·G C Palmer
Jun 18, 1977·British Medical Journal·D C SkeggJ Perry
Jan 1, 1973·Acta Psychiatrica Scandinavica·L CoviE H Uhlenhuth
Jan 19, 1980·Lancet·T R Einarson
May 10, 1980·British Medical Journal·J G Howe
Apr 19, 1980·British Medical Journal·R G Priest
Feb 20, 1961·Psychopharmacologia·L E HOLLISTERR O DEGAN

❮ Previous
Next ❯

Citations

Jan 1, 1995·New Directions for Mental Health Services·J M Ellison, C Pfaelzer
Jan 1, 1984·Psychopharmacology·P R MartinI J Kopin
Jan 1, 1984·European Journal of Clinical Pharmacology·U Klotz, I W Reimann
Jan 1, 1991·European Archives of Psychiatry and Clinical Neuroscience·D Garcia-BorregueroH M Emrich
Jan 1, 1984·Journal of Psychiatric Research·P Tyrer, R Owen
Jan 1, 1990·Journal of Psychiatric Research·G D BurrowsP F Marriott
Jan 1, 1990·Journal of Psychiatric Research·R L DuPont
Jan 1, 1993·Journal of Psychiatric Research·G D BurrowsT R Norman
Jan 1, 1993·Journal of Psychiatric Research·P P Roy-ByrneR K Ries
Jan 1, 1993·Journal of Psychiatric Research·J C Pecknold
Jan 1, 1983·Journal of Psychosomatic Research·P Tyrer
Apr 1, 1983·Neuropharmacology·M Lader, H Petursson
Jan 1, 1985·Neuroscience and Biobehavioral Reviews·R R GriffithsJ V Brady
Jan 1, 1987·Pharmacology & Therapeutics·S E File, S Pellow
Aug 1, 1984·Journal of Affective Disorders·P TyrerS Dawling
Sep 1, 1987·Journal of Affective Disorders·J Ananth
Jul 1, 1989·Journal of Affective Disorders·D Turkington, P Gill
May 1, 1990·Journal of Affective Disorders·P TyrerP Riley
Mar 1, 1992·Journal of Affective Disorders·M L Tattersall, C Hallstrom
Apr 1, 1992·Journal of Affective Disorders·A HoltonP Tyrer
Aug 1, 1993·Psychiatry Research·P MoodleyM Lader
Jan 1, 1991·Social Science & Medicine·C Gudex
Jan 1, 1991·Social Science & Medicine·J Gabe, M Bury
Jan 1, 1983·Progress in Neuro-psychopharmacology & Biological Psychiatry·I L Martin
Jan 1, 1984·Progress in Neuro-psychopharmacology & Biological Psychiatry·M Lader
Jan 1, 1988·Progress in Neuro-psychopharmacology & Biological Psychiatry·G CrouchC Hallstrom
Jan 1, 1991·Journal of Substance Abuse Treatment·N S Miller, M S Gold
Jan 1, 1991·Journal of Substance Abuse Treatment·B Alexander, P J Perry
Jan 1, 1991·Journal of Substance Abuse Treatment·H Ashton
Jan 1, 1991·Journal of Substance Abuse Treatment·S Juergens
Jan 1, 1991·Journal of Substance Abuse Treatment·M Lader
Jan 1, 1996·European Psychiatry : the Journal of the Association of European Psychiatrists·G CassanoM Garreau
Nov 1, 1990·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·S J CooperA Gilliland
Dec 1, 1993·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·J W van der LaanG de Groot
Jun 1, 1994·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·M Lader
Jul 6, 2000·Pharmacology, Biochemistry, and Behavior·E E Elliot, J M White
Aug 18, 2001·Pharmacology, Biochemistry, and Behavior·M F PérezO A Ramirez
Sep 1, 1997·Pharmacology, Biochemistry, and Behavior·E P WalaX Jing
Jun 25, 1983·Lancet·P TyrerS Dawling

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.